Abstract
Objective To investigate the effect and safety of tirofiban in PCI patients with non-ST elevation acute coronary syndrome(NSTE-ACS). Methods 80 high-risk patients were randomly divided into treatment group(tirofiban+ PCI) and control group(PCI). Collected all the clinical and coronary angiography.The coronary reperfusion flow(TIMI grade) of the culprit vessel after PCI, ultrasound cardiogram 1 week after PCI, bleed events, major adverse cardiac events with 30 days and one year, and heart function status were compared between the two groups. Results TIMI after PCI, major adverse cardiac events within 30 days, heart function status after one year, revascularization within 1 year in the treatment group were superior to the control group(χ2=42, 3, 2, 28, all P<0.05). Conclusion Tirofiban is safe and effective for elderly patients with NSTE-ACS received PCI. Key words: Myocardial infarction; Tirofiban; Interventional therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
